

PRESS RELEASE | BEIJING, CHINA - April 6, 2023

During the meeting between the President of the People's Republic of China H.E. Mr. Xi Jinping and the President of the French Republic, Mr. Emmanuel Macron, Mr. Pierre Luzeau, CEO of Seqens announces investment projects in sustainable production of essential molecules in China

During the visit of the President of the French Republic to China, the Seqens group has highlighted its historical support for a lasting Franco-Chinese friendship and its commitment to maintain and develop its complementary and value-creating activities in France and China.

Since its creation 20 years ago, Seqens has become a world leader in the development and production of active pharmaceutical ingredients (APIs), pharmaceutical intermediates and specialty ingredients by investing in all its sites, particularly in France and China, in the sustainable production of safer and more environmentally friendly essential molecules.

On the occasion of this important visit, Seqens and the Chinese and French authorities were able to salute once again the extraordinary mobilization of the Chinese teams of Seqens to guarantee a production of paracetamol and paracetamol even at the height of the health crisis.

And, thanks to its historical position in China, Seqens has announced an investment of nearly 300mRMB in **three major new production capacity projects in China** for the healthcare and cosmetics markets. These three projects will complement Seqens' industrial facilities and investments in Europe with sustainable and competitive production closer to local markets and will support the growing demand of the healthcare and cosmetics markets for safe and sustainable products.

"I am particularly proud of the recognition of the Chinese and French authorities for the mobilization of the teams at our Taixing and Wuxi sites, which enabled us to maintain essential production at the height of the covid crisis. And, convinced that a lasting Franco-Chinese friendship is both necessary and mutually beneficial, after having invested massively in Europe to strengthen our production of active pharmaceutical ingredients and essential pharmaceutical intermediates, we have decided to rely on local teams to launch 3 great projects in China and thus further strengthen the group's position as a leader committed to sustainable and competitive production as close as possible to our customers," says Mr. Pierre Luzeau, CEO of the Seqens group.

"I would like to thank the Seqens Group and also the local authorities of Taixing City and the Taxing Economic Development Zone for their renewed confidence and support with these three ambitious projects that will allow us to develop our high value-added activities for the manufacture of safer and more sustainable products in China," confirms Mr. Zhaoming Zhou, Director of the Taixing site and Vice-Chairman of the Yangzi Pharmaceuticals Board.

About SEQENS:

SEQENS is a world leader in the development and production of active ingredients, pharmaceutical intermediates and specialty ingredients, with 24 production sites, 10 R&D centers and 3,400 employees on three continents.

An integrated player across the entire value chain - from raw materials to active ingredients and from research and development to industrialization - SEQENS offers a broad portfolio of active ingredients, pharmaceutical intermediates, cosmetic ingredients and specialty chemicals, develops and industrializes the most demanding molecules, and relies on its ability to innovate, develop and implement the best available technologies.

Driven by a culture of excellence and a strong entrepreneurial spirit, our employees are committed to providing our customers with the highest level of service and quality while acting ethically in accordance with our environmental, social and governance program.

press@seqens.com / www.seqens.com / LinkedIn : SEQENS / Twitter : @seqens_group